LOS ANGELES, CA / ACCESSWIRE / February 24, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endologix, Inc. ("Endologix" or the "Company") (ELGX) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Endologix shares between August 2, 2016 and November 16, 2016 inclusive (the "Class Period"), are encouraged to contact the firm prior to March 6, 2017, also known as the lead plaintiff motion deadline.
To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at email@example.com.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
Nellix is Endologix's endovascular aneurysm sealing system used against infrarenal abdominal aortic aneurysms. Endologix allowed the Nellix system to be applied in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study. However, Endologix revealed that the FDA asked for a follow-up on patients in the EVAS-FORWARD-IDE study to measure Nellix. On December 27, 2016 Endologix revealed that it was barring AFX Endovascular AAA System shipments indefinitely because of a manufacturing investigation. When this news was shared with the investing public, Endologix stock fell, causing shareholders serious harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Lundin Law PC
Brian Lundin, Esq.
SOURCE: Lundin Law PC